| Stage | ESI | % of rev | CBT | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $995M | 100.00% | $982M | 100.00% | ESI ×1.01 |
| Gross profit | $342M | 34.40% | $184M | 18.74% | ESI +15.7pp |
| Operating income | $114M | 11.44% | $98M | 9.98% | ESI +1.5pp |
| Pre-tax income | $93M | 9.37% | $58M | 5.91% | ESI +3.5pp |
| Net income | $66M | 6.60% | $14M | 1.43% | ESI +5.2pp |
| Stage | ESI | CBT | Gap · A − B |
|---|---|---|---|
| Revenue | $995M100.00% | $982M100.00% | ESI ×1.01 |
| Gross profit | 34.40%$342M | 18.74%$184M | ESI +15.7pp |
| Operating income | 11.44%$114M | 9.98%$98M | ESI +1.5pp |
| Pre-tax income | 9.37%$93M | 5.91%$58M | ESI +3.5pp |
| Net income |
| 6.60%$66M |
| 1.43%$14M |
| ESI +5.2pp |
No disclosed counterparties: ESI, CBT.